Filing Details
- Accession Number:
- 0001640455-18-000024
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-03-07 19:00:36
- Reporting Period:
- 2018-03-05
- Accepted Time:
- 2018-03-07 19:00:36
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1640455 | Jounce Therapeutics Inc. | JNCE | Biological Products, (No Disgnostic Substances) (2836) | 454870634 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1693456 | Elizabeth Trehu | C/O Jounce Therapeutics, Inc. 780 Memorial Drive Cambridge MA 02139 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-03-05 | 4,545 | $4.02 | 4,545 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-03-05 | 3,179 | $21.24 | 1,366 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-03-05 | 1,366 | $22.11 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2018-03-05 | 4,545 | $0.00 | 4,545 | $4.02 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 246,805 | 2025-11-12 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to the trades.
- Represents the weighted average share price of an aggregate total of 3,179 shares sold in the price range of $20.86 to $21.70 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- Represents the weighted average share price of an aggregate total of 1,366 shares sold in the price range of $21.98 to $22.22 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 25% of the option shares vested and became exercisable on November 3, 2016 and the remainder of the option shares vest and become exercisable in 12 quarterly installments thereafter.
Billionaire Hedge Funds
